Pulmonary hypertension in polymyositis-dermatomyositis: clinical and hemodynamic characteristics and response to vasoactive therapy.
The increased incidence of pulmonary hypertension and its association with decreased survival is well-recognised in patients with systemic sclerosis. This association is not widely appreciated in patients with polymyositis-dermatomyositis. We report clinical and hemodynamic characteristics and response to vasoactive therapy in three patients with polymyositis-dermatomyositis and pulmonary hypertension and discuss them in light of the available literature.
Minai
O A
OA
Department of Pulmonary, Allergy, and Critical Care, Cleveland Clinic, Cleveland, Ohio 44195, USA. minaio@ccf.org
D000328:Adult; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003882:Dermatomyositis / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D017809:Fatal Outcome; D005260:Female; D006439:Hemodynamics; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000209:etiology; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000150:complications; D014665:Vasodilator Agents / Q000627:therapeutic use
D002317:Cardiovascular Agents; D014665:Vasodilator Agents